Archive for September, 2011

Derma sees partner for new drug in first half 2012

September 15th, 2011

Derma Sciences Inc expects to find a deep-pocketed partner for its treatment for diabetes-induced foot ulcers in the first half of 2012, even before it enrolls patients for late-stage trials. Derma Sciences specializes in products that treat wounds from common burns to deep skin gashes, with annual revenue of $56.5 million.

Its newest product, a topical gel dubbed DSC127, could reap over $1 billion in worldwide annual sales if approved, according to its chief executive. “We are fielding inquiries from a number of multinational pharmaceutical companies about DSC127,” CEO Edward Quilty told Reuters in an interview, without providing any details. “There is a high likelihood that the partnering will happen before we enroll the first patient in the Phase 3 trial.”
» Read more: Derma sees partner for new drug in first half 2012

Vitamin D levels tied to colon cancer risk

September 5th, 2011

A new analysis of earlier research finds that both higher vitamin D intake and higher blood levels of the vitamin’s active form are linked to lower risk of colon and rectal cancers. In 18 studies that included more than 10,000 people, colon cancer risk was as much as 33 percent lower in subjects with the highest blood levels of vitamin D compared to those with the lowest levels, researchers report in the Journal of Clinical Oncology. Those with the highest intake of vitamin D through supplements and food had 12 percent lower risk than those with the lowest intakes.

The total of studies available for analysis is still sparse, noted senior author Dr. Huanlong Qin and his colleagues from The Sixth People’s Hospital affiliated with Shanghai Jiao Tong University in Shanghai. Additional studies would be “highly desirable to enable more precise estimates and a better understanding of the role of vitamin D in colorectal cancer carcinogenesis,” they write.
» Read more: Vitamin D levels tied to colon cancer risk